Seizure freedom without intolerable adverse effects is patients’ main goal of epilepsy treatment and remains essential to the patient’s quality of life1.
The impact of uncontrolled seizures on patient health is high. Compared with being seizure free, patients with uncontrolled seizures (one or more seizures within the past five years) are:2*
more likely to have depression
more likely to be prevented
more likely to experience stigma in their daily lives
more likely to have poorer health†
as likely to have limited education
more likely to have restrictions in employment
In a large, multicentre study of patients with drug-resistant
epilepsy, health-related quality of life was not influenced by
reductions in seizure frequency that did not achieve seizure
The ultimate goal in epilepsy therapy should be freedom from seizures without adverse events.4
*Data from the Survey of Living with Neurological Conditions in Canada (SLNCC). Figures are odds ratios, adjusted for age and sex.2
†Measured using the Health Utility Index, an assessment of health status and quality of life in eight domains (hearing, vision, speech, mobility, dexterity, emotion, cognition, and pain).2
Freedom from seizures without side effects can be considered the most clinically relevant outcome of epilepsy therapy.4
Despite the impact of uncontrolled seizures on the health and quality of life of people with epilepsy,2,3 an estimated 36% of people with epilepsy continue to have seizures, even with advances in therapy.5
Managing the risks of continuing seizures to the health and lives of these people, and helping them maintain their quality of life, can represent a major challenge for the clinician and care team.
1. Halford JJ, Edwards JC. Seizure freedom as an outcome in epilepsy treatment clinical trials. Acta Neurol Scand 2020;142:91-107.
2. Josephson CB, et al. The impact of seizures on epilepsy outcomes: a national community-based survey. Epilepsia 2017;58(5):764-71.
3. Luoni C, et al. Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia. 2011;52(12):2181-91.
4. Kwan P, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51(6):1069-77.
5. Chen Z, et al. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs. JAMA Neurol 2018;75(3):279-86
P-UK-CE-2100043 December 2021